Core Viewpoint - Fuhong Hanlin (02696) shares rose over 4% following the FDA approval of its biosimilar drug POHERDY, making it the first interchangeable biosimilar of PERJETA in the U.S. market [1] Group 1: Company Developments - Fuhong Hanlin's stock increased by 4.11%, reaching HKD 67.1, with a trading volume of HKD 31.4021 million [1] - The FDA approved the biosimilar injection of pertuzumab, POHERDY, which can be used interchangeably with the original product PERJETA, covering all indications approved for the original product in the U.S. [1] - POHERDY is noted as the first biosimilar of pertuzumab in the U.S. and the first interchangeable biosimilar approved for cancer treatment by the FDA [1] Group 2: Market Position - Fuhong Hanlin has submitted marketing applications for HLX11 in China, Europe, and Canada, which have been accepted [1] - The company has a total of seven products approved for sale overseas, with four of those products receiving approval in the U.S. [1]
复宏汉霖现涨超4% POHERDY在美获批上市 可覆盖原研产品所有适应症